Targets › MESOTHELIN
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Apr 2027.
Open in Phaseline: the race on MESOTHELIN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | iCasp9M28z T cells Anti-mesothelin CAR-T cells with inducible caspase-9 safety switch | MESOTHELIN | Phase 1 | Malignant Pleural Disease | Apr 2027 |
Malignant Pleural Disease (1)
mixed (1)
Memorial Sloan Kettering Cancer Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.